These patents are valid through 2034 and 2026 respectively, the company said in a BSE filing.

"We are pleased by the grant of these patents to Suven for our pipeline of molecules in the CNS (central nervous system) arena, which are being developed for cognitive disorders with high unmet medical need with a huge market potential globally," Suven Life CEO Venkat Jasti said.

Suven Life said the granted claims of the patents are being developed as therapeutic agents and are useful in treatment of cognitive impairment associated with neurodegenerative disorders like Alzheimer's disease, Parkinson and Schizophrenia.

Its shares were trading 2.36 per cent up at Rs 195.05 per scrip on BSE.

Subscribe ETHealthworld Newsletter

Health Wallet not only addresses the current needs of the customers by paying for their hospitalisation and OPD expenses that are usually not covered by health insurance policies, but also ensures affordability of continuing their policy in later years.